future of glp 1 GLP-1 rec agonists have evolved over the past 20+ years as game-changers for type 2 diabetes to highly effective medications for the treatment obesity by targeting the neurometabolic pathophysiology of obesity The Future of GLP-1s

In the past ten years, a series of Phase III trials showed that the synthetic GLP-1/GIP agonists are effective in lowering blood sugar in type 2 diabetic subjects who were both treatment-nave or on typical first-line therapies such as metformin and insulin

These mechanisms are intricately interconnected, ultimately impairing bone remodeling and homeostatic balance

Once-weekly cagrilintide for weight management in people with overweight and obesity: A multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial

10.1073/pnas.1317834111 44 LiuS.YouL.ZhaoY.ChangX

Glucocorticoid receptor translational isoforms underlie maturational stage-specific glucocorticoid sensitivities of dendritic cells in mice and humans